X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development FDA Approvals

Lilly, AZ, AbbVie, And J&J Could Be Hurt By Medicare Bill

Content Team by Content Team
2nd August 2022
in FDA Approvals, News
Lilly, AZ, AbbVie, And J&J Could Be Hurt By Medicare Bill

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Could the SenateĀ adopt a “watershed” bill allowing drug price discussions after years of government inaction regarding medication prices in the U.S.? Analysts are busy studying the information at hand to determine how the legislation would impact the leading companies in the sector, but much remains to be seen.

According to analysts with SVB Securities, four major pharmaceutical companies- Eli Lilly, AstraZeneca, AbbVie, and Johnson & Johnson, are highly exposed to the current Medicare bargaining plan. Medicare is where the firms market a variety of valuable oncology and diabetic medications.

As drafted, the measure would allow Medicare to control drug pricing for 10 medications in 2026, increasing to 60 by 2029, according to the experts. As stated by the SVB team, Medicare would only regulate Part D drug prices in 2026 and 2027, but in 2028 it would be able to bargain for prices in Part B, where clinicians administer medicines.

Depending on whether they are small molecules or biologics, medications would become acceptable for Medicare negotiations following nine or thirteen years on the market. But the SVB analysts noted that because pharmaceutical firms frequently obtain exclusivity for far longer periods of time than both nine and 13 years, the bill runs the risk of severing the tail of lucrative medication sales. Darzalex, a medication for multiple myeloma, as well as the cancer treatments Tagrisso and Calquence from AstraZeneca, are among the medications that could lose their “tail” in the future.

Medicare would no longer attempt to negotiate rates for medications that have generic or biosimilar competitors, the SVB team noted.

The SVB analysts expressed their concern in a report, saying that they are concerned about the detrimental effect of the pending bill on future innovation and the finances connected with some of the most useful pharmaceuticals for Medicare consumers. Innovators’ desire to create new treatments, in particular small-molecule therapy for seniors, would probably decline. Not to mention that the finances for several drugs willĀ be reduced before the loss of exclusivity.

Because biosimilar versions of Merck’s top-selling oncology medication Keytruda are anticipated to hit the market in 2028, the first year that Part B drugs will be covered, the analysts pointed out that Merck doesn’t have significant exposure to the idea.

But the discussions are still shrouded in mystery. Analysts are awaiting the final legislation as well as word on the Senate parliamentarian’s position on the bill’s teeth, which would provide Medicare negotiation leverage. And it’s uncertain whether the Senate will be able to enact the legislation before it breaks for the week at its conclusion.

Biopharma has defended itself as recent congressional debates have progressed. The Medicare negotiation proposal was branded misguided and would end up harming the very patients and seniors that legislators claim to be helping, according to the president and CEO of the trade organization, the Biotechnology Innovation Organization, Michelle McMurry-Heath,Ā who made this statement in July.

In their analysis of the information provided, the SVB researchers identified two positive aspects and five downsides for the pharmaceutical business. On the plus side, the analysts noted that because of their anticipated loss of monopoly later in the decade, many of today’s top medications do not face significant exposure. Furthermore, since Part B pharmaceuticals won’t be added until 2028, many currently popular treatments won’t experience much of a change.

Analysts estimate that for the industry, the drawbacks outweigh the advantages. For starters, the additional reductions would be applied to grossĀ costs, although businesses already provide Medicare with large rebates. According to the SVB team, this could require businesses to make large payments to the government relative to their stated net sales.

Furthermore, substantial danger would exist for goods like CAR-T treatments and vaccinations, which were anticipated to be secure from biosimilar competition.

SVB has a long list of issues, but the team also cautioned that if the bill is passed, the government may become more active in the future on medicine pricing.

Despite the popularity of the issue among voters, lawmakers and American leaders have been publicly criticising excessive prescription prices for years without being able to accomplish any reform. Eight out of ten Americans supported government drug price initiatives in June, according to a West Health/Gallup survey, despite worries that the reform might hamper pharmaceutical innovation.

Previous Post

September May See Advent of Revised COVID-19 Booster Shots

Next Post

Novasep-PharmaZell Invests €7.3M to Increase API Production Capacity

Related Posts

idiopathic pulmonary fibrosis
Americas

US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

9th October 2025
Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
FastTrack Review
Americas

US FDA Launches Fast-Track Review Scheme for Generic Drugs

7th October 2025
AI Based Drug Discovery
Drug Development

Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

1st October 2025
API Manufacturing Facility
Americas

AbbVie Launches New API Manufacturing Facility in Illinois

1st October 2025
U.S. manufacturing
Americas

Amgen to Expand U.S. Manufacturing with $650M Investment

30th September 2025
Next Post
Novasep-PharmaZell Invests €7.3M to Increase API Production Capacity

Novasep-PharmaZell Invests €7.3M to Increase API Production Capacity

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

Ā© 2017 Copyright Ā© Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

Ā© 2017 Copyright Ā© Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In